Kiromic BioPharma, reports favorable eight-month follow-up results from the first patient enrolled in its Deltacel-01 Phase 1 clinical trial. This trial ...
Investment in Oxford Nanopore, innovators of a transformational new generation of sensing technology that today specialises in DNA/RNA sequencing &pou...
Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, announced the publication of a peer-reviewed stud...
Advanced Clinical, a privately held clinical research services organization committed to providing a better clinical experience across the drug developme...
The collaboration aims to identify and develop accessible and mini-invasive blood biomarkers specific to tau pathology in the brain These tools ...
Nexcella, Inc. a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and autoimmune disease, today announced tha...
Triastek Inc. ("Triastek"), a global leader in 3D printing pharmaceuticals, announced that it has entered into a research collaboration and platfor...
Agreement establishes Charles River as the preferred partner for Autobahn Labs, leveraging drug discovery and development capabilities to acceler...
Pfizer Inc. announced positive topline results from the Phase 3 AFFINE study (NCT04370054) evaluating giroctocogene fitelparvovec, an investigational gen...
Kronos Bio, a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, to...
Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostic products, provides an overview of advances supporting th...
Award supports preclinical research of Lario’s CaV2.3 calcium channel inhibitors as a novel disease-modifying approach for treatment of Par...
Innovent Biologics, a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of on...
Bristol Myers Squibb announced that the European Medicines Agency (EMA) validated its Type II variation application for Opdivo® (nivolumab) plu...
© 2025 Biopharma Boardroom. All Rights Reserved.
